Catyalyst Pharma (CPRX) Announces Publication of Firdapse Phase 3 Data in LEMS Patients
Tweet Send to a Friend
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
